Estimated risk of cardiovascular disease and secondary cancers with modern highly conformal radiotherapy for early-stage mediastinal Hodgkin lymphoma

M. V. Maraldo, N. P. Brodin, M. C. Aznar, I. R. Vogelius, P. Munck af Rosenschöld, P. M. Petersen, L. Specht

Research output: Contribution to journalArticle

87 Scopus citations


Hodgkin lymphoma (HL) survivors have an increased morbidity and mortality from secondary cancers and cardiovascular disease (CD). We evaluate doses with involved node radiotherapy (INRT) delivered as 3D conformal radiotherapy (3D CRT), volumetric modulated arc therapy (VMAT), or proton therapy (PT), compared with the extensive Mantle Field (MF). Patients and methods: For 27 patients with early-stage, mediastinal HL, treated with chemotherapy and INRT delivered as 3D CRT (30 Gy), we simulated an MF (36 Gy), INRT-VMAT and INRT-PT (30 Gy). Dose to the heart, lungs, and breasts, estimated risks of CD, lung (LC) and breast cancer (BC), and corresponding life years lost (LYL) were compared. Results: 3D CRT, VMAT or PT significantly lower the dose to the heart, lungs and breasts and provide lower risk estimates compared with MF, but with substantial patient variability. The risk of CD is not significantly different for 3D CRT versus VMAT. The risk of LC and BC is highest with VMAT. For LYL, PT is the superior modern technique. Conclusions: In early-stage, mediastinal HL modern radiotherapy provides superior results compared with MF. However, there is no single best radiotherapy technique for HL-the decision should be made at the individual patient level.

Original languageEnglish (US)
Pages (from-to)2113-2118
Number of pages6
JournalAnnals of Oncology
Issue number8
StatePublished - Aug 1 2013



  • Cardiovascular disease
  • Highly conformal radiotherapy
  • Hodgkin lymphoma
  • Involved node radiotherapy
  • Secondary cancers

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this